Prognostic Significance of Matrix Metalloproteinase-7 (MMP-7) Expression at the Invasive Front in Gastric Carcinoma

Xiu Ping Liu,1 Shigeto Kawauchi,1 Atsunori Oga,1 Kureo Tsushimi,2 Mutsuo Tsushimi,2 Tomoko Furuya1 and Kohsuke Sasaki1, 3

1Department of Pathology, Yamaguchi University School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi 755-8505 and 2Department of Surgery, Tsushimi Hospital, 413-1 Emukai, Hagi, Yamaguchi 758-0041

To evaluate the clinicopathological significance of matrix metalloproteinase-7 (MMP-7) expression in gastric carcinoma, we investigated immunohistochemically MMP-7 expression in 214 gastric carcinomas, and examined its relations with the clinicopathologic parameters including patient prognosis. MMP-7 expressed predominantly in cancer cells, and MMP-7-positive tumor cells were preferentially found in deeply invading nests, especially at the invasive front. The mean MMP-7 labeling index (LI) at the invasive front was significantly higher in tumors invading or penetrating the muscularis propria and in stages II–IV than within the submucosal layer and in stage I, respectively \( (P<0.001) \). Statistical analysis revealed that MMP-7 LI at the invasive front was related to lymph node metastasis, vascular invasion, and lymphatic permeation, when all 214 cases were examined as one group \( (P<0.05 \) for all), and the cases with high MMP-7 expression at the invasive front showed significantly more unfavorable prognosis as compared with that of low MMP-7 expression tumors \( (P<0.01) \). Multivariate analysis revealed that TNM stage and MMP-7 expression status at the invasive front were independent prognostic factors \( (P=0.0017, \text{RR}=3.12; P=0.0019, \text{RR}=2.67, \text{respectively}) \). Our findings indicated that expression of MMP-7 at the invasive front is closely associated with local invasiveness, and might be a reliable prognostic marker for patients with gastric carcinoma.

Key words: Gastric carcinoma — Matrix metalloproteinase-7 (MMP-7) — Immunohistochemistry — Prognosis

Two major characteristics of malignant tumor cells are invasion and metastasis, for which proteolytic degradation of the extracellular matrix, including basement membrane, by matrix metalloproteinases (MMPs) is one of the essential events.1, 2 MMP-7, one of the MMPs family members, has a broad spectrum of proteolytic activity against a variety of extracellular matrix substrates, including type IV collagens, proteoglycans, laminin, fibronectin and casein.3–5 It can also inactivate \( \alpha \)-antitrypsin, which augments the serine protease activity, resulting in activation of MMPs themselves.6 MMP-7 is expressed predominantly by tumor cells in various cancers.7–9 Immunohistochemical studies have shown that the expression of MMP-7 correlates with tumor invasion/metastasis and prognosis in both colorectal adenocarcinoma and esophageal squamous cell carcinoma.8–10

Gastric carcinoma is one of the most common cancers in Japan, and many patients die due to invasion or metastasis of cancer cells. Previous studies concerning MMP-7 expression in gastric carcinoma showed that the expression of MMP-7 mRNA and protein was higher in cancer tissue than in the surrounding normal tissue, and that it might be associated with tumor invasiveness and/or metastasis.7,11–13 However, the prognostic significance of MMP-7 expression in gastric carcinoma has not been reported yet. In the present study, we examined immunohistochemically MMP-7 expression in 214 gastric carcinomas to assess the relationships of MMP-7 expression to clinicopathologic parameters including patient prognosis in gastric carcinoma.

MATERIALS AND METHODS

Patients In this study, we used 214 cases of gastric carcinoma. All patients underwent curative surgery in the Tsushimi Hospital, Hagi, Yamaguchi, between January 1991 and December 1997, and received neither chemotherapy nor radiation therapy before surgery. Of these patients, 126 (58.9%) were men and 88 (41.1%) were women, with the mean age of 67 years (range: 30–93 years). All patients were followed-up after surgery until March 1, 2001. During the follow-up period, 20 patients (17 died of unrelated causes and 3 died within 30 days after surgery) were excluded, leaving 194 patients for survival analyses.

Pathological diagnosis including the depth of tumor invasion, vascular invasion, lymphatic permeation, and...
lymph node metastasis, was made according to the general rules for gastric cancer outlined by the Japanese Research Society for Gastric Cancer.14) The tumor stage was determined according to the 1997 TNM Classification System of the UICC,15) stage I (n=73), stage II (n=35), stage III (n=60), and stage IV (n=46). Histologic differentiation was graded well (n=53), moderate (n=74), or poor (n=87). The clinicopathologic findings were diagnosed by reviewing all hematoxylin and eosin (H & E) stained tissue sections.

Immunohistochemistry In this study, 4-µm thick paraffin sections were cut from each block of resected specimens, and mounted on slides. In each case, 1–3 paraffin sections containing the invasive front were selected for immunohistochemical staining. Immunostaining for MMP-7 was performed using a standard avidin-biotin peroxidase (ABC) technique. Sections were dewaxed in xylene, rehydrated in alcohol, and then heated in 10 mmol/liter sodium citrate buffer (pH 6.0) by a microwave oven (650 W) for 20 min to retrieve the antigen. The endogenous peroxidase activity was suppressed by a solution of 3% hydrogen peroxide in methanol for 5 min. After blocking of non-specific binding sites with 10% normal rabbit serum, slides were incubated overnight at 4°C with monoclonal antibody against MMP-7 (10 µg/ml, clone 141-7B2, Daichi Fine Chemicals, Ltd., Takaoka), in 1% bovine serum albumin (BSA)/phosphate-buffered saline (PBS), pH 7.6. Subsequent reaction, using a HISTOFINE SAB-PO (M) Immunohistochemical Staining Kit (Nichirei, Tokyo), was based on the streptavidin-biotin complex/horseradish peroxidase method. Positive reaction was visualized with hydrogen peroxide containing 3,3’-diaminobenzidine (DAB)/PBS. Sections were counterstained with Mayer’s hematoxylin for nuclei and mounted. Negative control sections was made by omitting the primary antibody.

Evaluation of MMP-7 staining MMP-7 labeling index (MMP-7 LI) at the invasive front was calculated as the percentage of cells stained positively for MMP-7 among tumor cells counted. Ten high-power fields were selected, and at least 1000 tumor cells were observed for evaluation. All calculations were independently performed twice and cases of twice-counted disagreements were reviewed, followed by a conclusive judgement.

Statistical analysis Data are shown as the mean± standard deviation (±SD). MMP-7 LI was compared between different clinicopathological subgroups using a nonparametric Mann-Whitney U test or Kruskal-Wallis test. Univariate and multivariate survival analyses were performed according to the Kaplan-Meier method and proportional hazard regression model, respectively. For all statistical tests, a P value less than 0.05 was defined as statistically significant.

RESULTS

Features of MMP-7 expression The cytoplasm and cell membrane were stained for MMP-7 in tumor cells (Fig. 1). The antral gland epithelium was rarely positive and stromal cells were negative for MMP-7 staining. The distribution of MMP-7-positive tumor cells varied from area to area, but the cells were frequently located in deeply invading tumor cell nests, especially at the invasive front (Fig. 2). MMP-7-positive tumor cells were found in 8 of 46 mucosal cancers (17.4%), 14 of 38 submucosal cancers (36.8%), 22 of 33 cases invading the muscularis propria (66.7%), 28 of 39 tumors invading subserosa (71.8%), and 43 of 58 cancers invading serosa (74.1%).

Relationship of MMP-7 expression with the depth of tumor invasion The mean MMP-7 LI at the invasive front increased with the depth of tumor invasion. The mean MMP-7 LI of cancers invading mucosa, submucosa, muscularis propria, subserosa and serosa, determined based on histologic evaluation, was 6.7±10.7% (n=46), 7.7±13.7% (n=38), 23.6±14.4% (n=33), 26.9±14.6%
(n=39), and 28.2±13.9% (n=58), respectively. The mean MMP-7 LI at the invasive front was significantly higher in “advanced cancers” (tumors of muscularis propria or beyond) than in “so-called early cancers” (mucosal or submucosal tumors) (P<0.001).

Relationships of MMP-7 expression to clinicopathologic features Table I summarizes the relationships of MMP-7 LI at the invasive front to clinicopathological features in 214 gastric carcinomas. The mean MMP-7 LI was significantly higher in stage II–IV and T2–4 tumors, and cancers with lymph node metastasis, vascular invasion, and/or lymphatic permeation than in stage I and T1 tumors, and cancers with none of them (P<0.05 for all). However, histological differentiation of tumors did not affect MMP-7 LI.

Based on T classification of tumors, the 214 cases were classified into 4 groups. The relationships between MMP-7 LI at the invasive front and lymph node metastasis, vascular invasion, and lymphatic permeation were further analyzed in each group, but no significant relationship between them was found in any group (data not shown).

### Table I. Associations of MMP-7 Expression at the Invasive Front with Clinicopathologic Factors

| Factor                        | No.  | MMP-7 LI (%) (mean±SD) | P value |
|-------------------------------|------|------------------------|---------|
| Total no. of patients        | 214  |                        |         |
| Gender                        |      |                        |         |
| Male                          | 126  | 16.7±18.4              |         |
| Female                        | 88   | 18.9±21.6              | NS      |
| Age                           |      |                        |         |
| ≥67                           | 130  | 17.5±19.9              |         |
| <67                           | 84   | 17.8±19.3              | NS      |
| Lymph node metastasis        |      |                        |         |
| Negative                      | 108  | 12.8±16.7              | <0.05   |
| Positive                      | 106  | 24.1±21.3              |         |
| TNM stage                     |      |                        |         |
| I                             | 73   | 11.4±15.4              |         |
| II                            | 35   | 24.6±24.2              |         |
| III                           | 60   | 26.1±21.2              |         |
| IV                            | 46   | 29.3±20.3              | <0.05   |
| Histologic differentiated    |      |                        |         |
| Well differentiated           | 53   | 20.6±18.5              |         |
| Moderately differentiated     | 74   | 20.4±21.1              |         |
| Poorly differentiated         | 87   | 24.9±10.1              | NS      |
| Lymphatic permeation          |      |                        |         |
| Negative                      | 70   | 9.8±15.4               |         |
| Positive                      | 144  | 21.4±20.56             | <0.001  |
| Vascular invasion             |      |                        |         |
| Negative                      | 114  | 13.4±17.7              |         |
| Positive                      | 100  | 22.3±20.8              | <0.05   |

SD, standard deviation; LI, labeling index.

**Relationship of MMP-7 expression to patients’ survival**

Thirty percent was selected as the cutoff value of MMP-7 LI at the invasive front by testing the most significant cutoff value referring to the distribution chart of the MMP-7 LI at the invasive front and survival period.16, 17) Using the log-rank test, disease-specific survival time of patients with gastric carcinoma having high MMP-7 expression at the invasive front (MMP-7 LI≥30%) was shorter than that of patients with low MMP-7-expressing tumors (MMP-7 LI<30%) (Fig. 3; P<0.01). Univariate survival analysis revealed that in addition to MMP-7 LI, tumor size, histologic differentiated type, depth of tumor invasion, TNM stage, lymph node metastasis, vascular invasion, and lymphatic permeation were significantly associated with disease-specific survival (Table II, P<0.05 for all). Multivariate survival analysis disclosed that of these parameters, only tumor stage (P=0.0017, relative risk (RR)=3.12) and expression status of MMP-7 at the invasive front (P=0.0019, RR=2.67) were independent prognostic factors (Table II).

**DISCUSSION**

MMP-7 was expressed predominantly in deeply invading tumor cell nests, especially at the invasive front. This is in accordance with the report by Adachi et al. in gastric carcinomas.11) MMP-7 is known to play an important role in tumor invasion,7–10) and MMP-7 expression at the invasive front should more accurately represent tumor invasive activity. Therefore, we selected MMP-7 LI at the invasive front for analyzing the association of MMP-7 expression with clinicopathologic features in this study. Our results demonstrated that the percentage of MMP-7-positive cases increased with the depth of tumor invasion, and the mean MMP-7 LI at the invasive front was significantly higher in advanced cancer than in early cancer. These observations suggest that MMP-7 expression affords invasive character.
to tumor cells, resulting in the progression of gastric carcinoma.

In some reports concerning MMP-7 in gastric carcinoma, MMP-7 expression was significantly associated with clinicopathologic features such as the depth of tumor invasion, lymph node metastasis, vascular vessel invasion, and/or lymphatic permeation. However, Senota et al. reported that the level of MMP-7 mRNA was linked only to tumor invasion depth at the gastric wall. In our study of 214 cases, MMP-7 LI at the invasive front correlated significantly with the invasive depth at the gastric wall. The mean MMP-7 LI at the invasive front was significantly higher in carcinomas with lymph node metastasis, vascular vessel invasion, and/or lymphatic permeation than in those without any of them. However, when 214 cases were classified into four groups based on T classification of tumor, such a relationship was not found in the separate groups. This may support the view that expression of MMP-7 well represents tumor invasiveness, especially local invasiveness. Some researchers have indicated that the changes of other molecules, such as adhesion molecules, motility factors, and sugar chains are required for lymph node metastasis, vascular vessel invasion, and lymphatic permeation. Yamashita et al. reported that the positive ratio of MMP-7 was significantly higher in intestinal-type than in diffuse-type gastric carcinoma. Data from Honda et al. and our studies, however, indicate that MMP-7 expression was not affected by histological type.

Table II. Univariate and Multivariate Analyses of Disease-specific Survival for 194 Patients with Gastric Carcinoma

| Prognostic factors | Univariate | Multivariate |
|--------------------|------------|-------------|
|                    | P value<sup>a</sup> | Relative risk | 95% CI |
| Age (≥67 vs. <67)  | NS         | Not included |         |
| Sex (male vs. female) | NS       | Not included |         |
| Tumor size (<4.5 vs. ≥4.5) | <0.0001 | NS          |         |
| Histologically differentiated | 0.0107 | NS          |         |
| Depth of invasion  | <0.0001   | NS          |         |
| Lymph node metastasis (pos vs. neg) | <0.0001 | 0.0017 | 3.12 | 1.52–5.36 |
| TNM stage<sup>b</sup> | <0.0001 | NS          |         |
| Lymphatic permeation (pos vs. neg) | <0.0001 | NS          |         |
| Vascular invasion (pos vs. neg) | <0.0001 | NS          |         |
| MMP-7 expression (high vs. low) | <0.0001 | 0.0019 | 2.67 | 1.44–4.95 |

<sup>a</sup> P<0.05 was considered statistically significant.
<sup>b</sup> Stage was determined according to 1997 TNM Classification System of UICC.

To our knowledge, this is the first report to assess the correlation between MMP-7 expression and survival of patients with gastric carcinoma. Survival time of patients with gastric carcinoma expressing high levels of MMP-7 at the invasive front was shorter than that of patients with low MMP-7 expression. Moreover, multivariate survival analysis revealed that both TNM stage and MMP-7 expression status were independent prognostic factors. This was also reported to be the case in colorectal cancer and esophageal squamous cell carcinoma. These results suggest that the level of MMP-7 expression is a reliable prognostic marker, at least in gastric cancer. In addition, detection of MMP-7 would offer the opportunity for a novel therapeutic approach, i.e., MMP-7 could be a potential target for therapeutic intervention. The use of synthetic broad-spectrum MMP inhibitors is one of the possible strategies. Taking our results into consideration, MMP-7 could be a primary target of such inhibitors in gastric carcinoma. Thus, the immunohistochemical analysis of MMP-7 in gastric carcinoma tissues could provide basic data for a new therapeutic strategy via broad-spectrum and/or selective MMP inhibitors.

In conclusion, we demonstrated that MMP-7 expression at the invasive front is linked with the invasive depth at the gastric wall. The expression of MMP-7 was found to be an independent prognostic factor in patients with gastric carcinoma.

(Received October 17, 2001/Revised December 6, 2001/ Accepted December 13, 2001)

REFERENCES

1) Crawford, H. C. and Matrisian, L. M. Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression. Invasion Metastasis, 14, 234–245 (1995).
Expression of MMP-7 in Gastric Carcinoma

2) Stetler-Stevenson, W. G., Aznavoorian, S. and Liotta, L. A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. *Annu. Rev. Cell Biol.*, 9, 541–573 (1993).

3) Matrisian, L. M. The matrix-degrading metalloproteinases. *Bioessays*, 14, 455–463 (1992).

4) Miyazaki, K., Hattori, Y., Umenishi, F., Yasumitsu, H. and Umeda, M. Purification and characterization of extracellular matrix-degrading metalloproteinase, matrin (pump-1), secreted from human rectal carcinoma cell line. *Cancer Res.*, 50, 7758–7764 (1990).

5) Wilson, C. L. and Matrisian, L. M. Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. *Int. J. Biochem. Cell Biol.*, 28, 123–136 (1996).

6) Sires, U. I., Murphy, G., Baragi, V. M., Fliszar, C. J., Welgus, H. G. and Senior, R. M. Matrilysin is much more efficient than other matrix metalloproteinases in the proteolytic inactivation of alpha 1-antitrypsin. *Biochem. Biophys. Res. Commun.*, 204, 613–620 (1994).

7) Honda, M., Mori, M., Ueo, H., Sugimachi, K. and Akiyoshi, T. Matrix metalloproteinase-7 expression in gastric carcinoma. *Gut*, 39, 444–448 (1996).

8) Yamamoto, H., Adachi, Y., Itoh, F., Iku, S., Matsuno, K., Kusano, M., Arimura, Y., Endo, T., Hinoda, Y., Hosokawa, M. and Imai, K. Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. *Cancer Res.*, 59, 3313–3316 (1999).

9) Yamashita, K., Mori, M., Shiraiishi, T., Shibuta, K. and Sugimachi, K. Clinical significance of matrix metalloproteinase-7 expression in esophageal carcinoma. *Clin. Cancer Res.*, 6, 1169–1174 (2000).

10) Adachi, Y., Yamamoto, H., Itoh, F., Arimura, Y., Nishi, M., Endo, T. and Imai, K. Clinicopathologic and prognostic significance of matrilysin expression at the invasive front in human colorectal cancers. *Int. J. Cancer*, 95, 290–294 (2001).

11) Adachi, Y., Itoh, F., Yamamoto, H., Matsuno, K., Arimura, Y., Kusano, M., Endoh, T., Hinoda, Y., Oohara, M., Hosokawa, M. and Imai, K. Matrix metalloproteinase matrilysin (MMP-7) participates in the progression of human gastric and esophageal cancers. *Int. J. Oncol.*, 13, 1031–1035 (1998).

12) Yamashita, K., Azumano, I., Mai, M. and Okada, Y. Expression and tissue localization of matrix metalloproteinase 7 (matrilysin) in human gastric carcinomas. Implications for vessel invasion and metastasis. *Int. J. Cancer*, 79, 187–194 (1998).

13) Senota, A., Itoh, F., Yamamoto, H., Adachi, Y., Hinoda, Y. and Imai, K. Relation of matrilysin messenger RNA expression with invasive activity in human gastric cancer. *Clin. Exp. Metastasis*, 16, 313–321 (1998).

14) Nishi, M., Omori, Y. and Miwa, K. “Japanese Research Society for Gastric Cancer. Japanese Classification of Gastric Carcinoma,” First English Ed. (1995). Kanehara & Co., Ltd., Tokyo.

15) Sobin, L. H. and Wittekind, Ch. “International Union against Cancer. TNM Classification of Malignant Tumors,” 5th Ed., pp. 59–62 (1997). John Wiley & Sons, Inc., New York.

16) Kawauchi, S., Goto, Y., Liu, X. P., Furuya, T., Oga, A., Oda, Y., Tsuneyoshi, M., Ibara, K. and Sasaki, K. Low expression of p27 (Kip1), a cyclin-dependent kinase inhibitor, is a marker of poor prognosis in synovial sarcoma. *Cancer*, 91, 1005–1012 (2001).

17) Liu, X. P., Kawauchi, S., Oga, A., Suehiro, Y., Tsushima, K., Tsushima, M. and Sasaki, K. Combined examination of p27(Kip1), p21Waf1/Cip1 and p53 expression allows precise estimation of prognosis in patients with gastric carcinoma. *Histopathology*, 39, 1–8 (2001).

18) Mayer, B., Johnson, J. P., Leitl, F., Jauch, K. W., Heiss, M. M., Schildberg, F. W., Birchmeier, W. and Funke, I. E-Cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. *Cancer Res.*, 53, 1690–1695 (1993).

19) Yamamoto, H., Itoh, F., Hinoda, Y. and Imai, K. Inverse association of cell adhesion regulator messenger RNA expression with metastasis in human colorectal cancer. *Cancer Res.*, 56, 3605–3609 (1996).

20) Miyazaki, K., Kimkawa, Y., Nakamura, A., Yasumitsu, H. and Umeda, M. A large cell-adhesive scatter factor secreted by human gastric carcinoma cells. *Proc. Natl. Acad. Sci. USA*, 90, 11767–11771 (1993).

21) Hakomori, S. Tumor malignancy defined by aberrant glycosylation and sphingolipid metabolism. *Cancer Res.*, 56, 5309–5318 (1996).

22) Nemunaitis, J., Poole, C., Primrose, J., Rosemurgy, A., Malfetano, J., Brown, P., Berrington, A., Cornish, A., Lynch, K., Rasmussen, H., Kerr, D., Cox, D. and Millar, A. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. *Clin. Cancer Res.*, 4, 1101–1109 (1998).